SlideShare una empresa de Scribd logo
1 de 18
Descargar para leer sin conexión
2018/12/13
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
https://doi.org/10.1093/cid/ciy1054
7 vs 14 RCT
• RCT
• 2 1
• P:
7 48
7
•
CVC
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
• /
CVC
CVC
•
•
• HIV 1 48
• 48 <60mmHg
• 24
• /
• 48 2 38℃ 1 38.5℃ 35.5℃
•
•
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
• I 7
• C: 14
•
• in vitro
•
•
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
90
•
•
a. 90
b.
c.
•
14
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
30
• Clostridium difficile
• 90
• 90
• 30 0
12
•
• 90
• 90
• 1.5 2.5
RIFLE
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
• 30
• 10 FDA
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
7
4807 2169
604
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al.
Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-
negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN
INFECT DIS. 2018 Dec 11.
• 90
45.8% 48.3%
-2.6% (95% CI -10.5% to 5.3%)
• Time to return to baseline activity
•
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
• 90
•
•
•
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
Appropriate empirical
therapy administered within
48 hours
260 (85.0) 242 (81.2)
Bacteria type c
E. Coli
Klebsiella spp.
Other Enterobacteriaceae
Acinetobacter spp.
Pseudomonas spp.
Other
186 (60.8)
47 (15.3)
40 (13.1)
2 (0.7)
28 (9.2)
3 (1)
194 (65.1)
33 (11.1)
43 (14.4)
4 (1.3)
20 (6.7)
4 (1.3)
MDR Gram-negative
bacteremia d
58 (18.9) 51 (17.1)
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
Source of bacteremia
Urinary tract 212 (69.3) 199 (66.8)
Primary bacteremia
Abdominal
Respiratory
Central venous catheter
Skin and soft tissue
23 (7.5)
37 (12.1)
14 (4.6)
15 (4.9)
5 (1.6)
28 (9.4)
34 (11.4)
10 (3.4)
23 (7.7)
4 (1.3)
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
Outcome Short arm (7
days)
N=306 patients
Long arm (14
days)
N=298 patients
Risk difference
(95% confidence
interval)
P-value
Primary outcome 140 (45.8) 144 (48.3) -2.6 (-10.5 to 5.3) 0.527
90 day all-cause
mortality
36 (11.8) 32 (10.7) 1.0 (-4.0 to 6.1) 0.702
Readmissions 119 (38.9) 127 (42.6) -3.7 (-11.5 to 4.1) 0.363
Extended hospitalization
beyond 14 days
15 (4.9) 19 (6.4) -1.5 (-5.1 to 2.2) 0.483
Distant complications 2 (0.7) 1 (0.3) - 1.0
Relapse of bacteremia 8 (2.6) 8 (2.7) -0.07 (-2.6 to 2.5) 0.957
Suppurative
complications
16 (5.2) 10 (3.4) 1.8 (-1.4 to 5.1) 0.257
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
New clinically or
microbiologically
documented infection
70 (22.9) 68 (22.8) 0.06 (-6.6 to 6.8) 0.987
Functional capacity needs
assistance/dependent in
ADL or bedridden at 30
150 (51.4) (292
patients)
163 (57.2) (285
patients)
-5.8 (-13.9 to 2.3) 0.031
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
days
Resistance development 33 (10.8) 29 (9.7) 1 (-3.7 to 5.9) 0.690
Time to return to baseline
activity in weeks (90
days)
2 (0-8.3) (218
patients)
3 (1-12) (222
patients)
0.010
Total hospital days (90
days from randomization)
- survivors
3 (1-9) (270
patients alive at
day 90)
3.5 (1-10) (266
patients alive at
day 90)
0.923
Total hospital days (90
days from randomization)
– all
4 (1-10) 4 (1-12) 0.603
Duration of appropriate
antibiotic therapy for
bacteremia
7 (7.0-8.0) 14.0 (14.0-14.0) <0.001
Total antibiotic days from
culture collection to day
90 post randomization
10.0 (9.0-18.0)
(270 patients
alive at day 90)
16.0 (15.0-22.0)
(266 patients alive
at day 90)
<0.001
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
Supplementary Table 1: Type of antibiotics
according to study group
Type of antibiotics a Short arm (306 patients) Long arm (298 patients)
Cephalosporins 157 (51.3) 167 (56.0)
Beta-lactam beta-lactamase
inhibitors
72 (23.5) 63 (21.1)
Quinolones b 15 (4.9) 14 (4.7)
Aminoglycosides 39 (12.7) 36 (12.1)
Carbapenems 23 (7.5) 16 (5.4)
Trimethoprim-sulfamethoxazole
0 2 (0.7)
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
A.	Intravenous	antibiotics
Type of antibiotics a Short arm (196 patients)
Long arm (242
patients)*
Quinolones 151 (77.0) 172 (71.1)
Beta-lactams 28 (14.3) 50 (20.7)
Trimethoprim-
Sulfamethoxazole
17 (8.7) 20 (8.3)
B.	Oral	antibiotics
Data are presented as numbers (percentage)
a
110 patients (35.9%) In the short duration arm and 56 (18.8%) In the long duration arm completed intra-venous
antibiotic course and did not receive oral antibiotics.
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy
for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.

Más contenido relacionado

La actualidad más candente

Tb sure ultra short july 2019
Tb sure ultra short july 2019Tb sure ultra short july 2019
Tb sure ultra short july 2019PathKind Labs
 
The new generation indian tcv - Zyvac TCV by Zydus Vaccines
The new generation indian tcv - Zyvac TCV by Zydus VaccinesThe new generation indian tcv - Zyvac TCV by Zydus Vaccines
The new generation indian tcv - Zyvac TCV by Zydus VaccinesGaurav Gupta
 
Typhoid conjugate vaccines in India - Aug 2015
Typhoid conjugate vaccines in India -  Aug 2015Typhoid conjugate vaccines in India -  Aug 2015
Typhoid conjugate vaccines in India - Aug 2015Gaurav Gupta
 
重症病患抗生素使用961113
重症病患抗生素使用961113重症病患抗生素使用961113
重症病患抗生素使用961113calaf0618
 
Acellular pertussis v/s wP - Current status
Acellular pertussis v/s wP - Current statusAcellular pertussis v/s wP - Current status
Acellular pertussis v/s wP - Current statusGaurav Gupta
 
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Gaurav Gupta
 
Dr.MK Sudarshan
Dr.MK SudarshanDr.MK Sudarshan
Dr.MK Sudarshanriacon
 
seminar of antibiotic in newborn
seminar of antibiotic in newbornseminar of antibiotic in newborn
seminar of antibiotic in newbornDr. Habibur Rahim
 
18. antibiotic use in the ic ul
18. antibiotic use in the ic ul18. antibiotic use in the ic ul
18. antibiotic use in the ic ulYerragunta Tirumal
 
Respiratory Viruses in Pediatric Age
Respiratory Viruses in Pediatric Age  Respiratory Viruses in Pediatric Age
Respiratory Viruses in Pediatric Age WAidid
 
WEBINAR - Zyvac tcv master class september 2018
WEBINAR - Zyvac tcv master class september 2018WEBINAR - Zyvac tcv master class september 2018
WEBINAR - Zyvac tcv master class september 2018Gaurav Gupta
 
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017Meningitis Research Foundation
 
M02 s03 l04 resistance salvana
M02 s03 l04 resistance salvanaM02 s03 l04 resistance salvana
M02 s03 l04 resistance salvanaKaterina Leyritana
 

La actualidad más candente (20)

Tb sure ultra short july 2019
Tb sure ultra short july 2019Tb sure ultra short july 2019
Tb sure ultra short july 2019
 
The new generation indian tcv - Zyvac TCV by Zydus Vaccines
The new generation indian tcv - Zyvac TCV by Zydus VaccinesThe new generation indian tcv - Zyvac TCV by Zydus Vaccines
The new generation indian tcv - Zyvac TCV by Zydus Vaccines
 
Typhoid conjugate vaccines in India - Aug 2015
Typhoid conjugate vaccines in India -  Aug 2015Typhoid conjugate vaccines in India -  Aug 2015
Typhoid conjugate vaccines in India - Aug 2015
 
重症病患抗生素使用961113
重症病患抗生素使用961113重症病患抗生素使用961113
重症病患抗生素使用961113
 
Acellular pertussis v/s wP - Current status
Acellular pertussis v/s wP - Current statusAcellular pertussis v/s wP - Current status
Acellular pertussis v/s wP - Current status
 
Research to practice - 5 papers of interest
Research to practice - 5 papers of interestResearch to practice - 5 papers of interest
Research to practice - 5 papers of interest
 
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
Zyvac tcv the Indian typhoid conjugate vaccination - Yamunanagar aug 2018
 
Strep Pneumoniae
Strep PneumoniaeStrep Pneumoniae
Strep Pneumoniae
 
Dr.MK Sudarshan
Dr.MK SudarshanDr.MK Sudarshan
Dr.MK Sudarshan
 
Antimicrobial therapy 2018 - Chihara
Antimicrobial therapy 2018 - ChiharaAntimicrobial therapy 2018 - Chihara
Antimicrobial therapy 2018 - Chihara
 
seminar of antibiotic in newborn
seminar of antibiotic in newbornseminar of antibiotic in newborn
seminar of antibiotic in newborn
 
18. antibiotic use in the ic ul
18. antibiotic use in the ic ul18. antibiotic use in the ic ul
18. antibiotic use in the ic ul
 
Respiratory Viruses in Pediatric Age
Respiratory Viruses in Pediatric Age  Respiratory Viruses in Pediatric Age
Respiratory Viruses in Pediatric Age
 
nature14411
nature14411nature14411
nature14411
 
WEBINAR - Zyvac tcv master class september 2018
WEBINAR - Zyvac tcv master class september 2018WEBINAR - Zyvac tcv master class september 2018
WEBINAR - Zyvac tcv master class september 2018
 
Borrow for web
Borrow for webBorrow for web
Borrow for web
 
What's new in c. diff
What's new in c. diffWhat's new in c. diff
What's new in c. diff
 
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017
Dr Adam Finn @ MRF's Meningitis & Septicaemia in children & Adults 2017
 
Active immunization in immunocompromised hosts
Active immunization in immunocompromised hosts Active immunization in immunocompromised hosts
Active immunization in immunocompromised hosts
 
M02 s03 l04 resistance salvana
M02 s03 l04 resistance salvanaM02 s03 l04 resistance salvana
M02 s03 l04 resistance salvana
 

Similar a グラム陰性菌菌血症治療期間

Tratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPTratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPPablo Francisco Parenti
 
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...hivlifeinfo
 
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...hivlifeinfo
 
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...UC San Diego AntiViral Research Center
 
GSK Clinical Trials Summary Q2 2022.pdf
GSK Clinical Trials Summary Q2 2022.pdfGSK Clinical Trials Summary Q2 2022.pdf
GSK Clinical Trials Summary Q2 2022.pdfCannlsoy1
 
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
 
Antibiotics in the management of chronic periodontitis.ppt
Antibiotics in the management of chronic periodontitis.pptAntibiotics in the management of chronic periodontitis.ppt
Antibiotics in the management of chronic periodontitis.pptmalti19
 
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...hivlifeinfo
 
Shifting paradigms in vaccinology immune modulation and sex differences explo...
Shifting paradigms in vaccinology immune modulation and sex differences explo...Shifting paradigms in vaccinology immune modulation and sex differences explo...
Shifting paradigms in vaccinology immune modulation and sex differences explo...WAidid
 
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBC
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBCReport Back from San Antonio Breast Cancer Symposium: Spotlight on MBC
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBCbkling
 
COVID-19 Clinical Development
COVID-19 Clinical DevelopmentCOVID-19 Clinical Development
COVID-19 Clinical DevelopmentManish Gupta
 
Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018hivlifeinfo
 
Patient safety goal 4 : Tackling Antimicrobial Resistance
Patient safety goal 4  : Tackling Antimicrobial ResistancePatient safety goal 4  : Tackling Antimicrobial Resistance
Patient safety goal 4 : Tackling Antimicrobial ResistanceHCY 7102
 
High Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHigh Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHopkinsCFAR
 
Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Fanoestudio.com
 
Zyvac TCV - The Indian Typhoid Conjugate Vaccine
Zyvac TCV - The Indian Typhoid Conjugate VaccineZyvac TCV - The Indian Typhoid Conjugate Vaccine
Zyvac TCV - The Indian Typhoid Conjugate VaccineGaurav Gupta
 
Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)RxVichuZ
 
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...Societat Catalana de Farmàcia Clínica
 
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASESDIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASESWAidid
 

Similar a グラム陰性菌菌血症治療期間 (20)

Tratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPTratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IP
 
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...
Contemporary Management of HIV. New Data From IDWeek 2018 and Other Fall 2018...
 
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
 
2016 Sessions: 3 recent advances in oi management
2016 Sessions: 3 recent advances in oi management2016 Sessions: 3 recent advances in oi management
2016 Sessions: 3 recent advances in oi management
 
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...
Addressing Drug Resistant Sexually Transmitted Infections: From the Bench to ...
 
GSK Clinical Trials Summary Q2 2022.pdf
GSK Clinical Trials Summary Q2 2022.pdfGSK Clinical Trials Summary Q2 2022.pdf
GSK Clinical Trials Summary Q2 2022.pdf
 
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
 
Antibiotics in the management of chronic periodontitis.ppt
Antibiotics in the management of chronic periodontitis.pptAntibiotics in the management of chronic periodontitis.ppt
Antibiotics in the management of chronic periodontitis.ppt
 
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...
 
Shifting paradigms in vaccinology immune modulation and sex differences explo...
Shifting paradigms in vaccinology immune modulation and sex differences explo...Shifting paradigms in vaccinology immune modulation and sex differences explo...
Shifting paradigms in vaccinology immune modulation and sex differences explo...
 
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBC
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBCReport Back from San Antonio Breast Cancer Symposium: Spotlight on MBC
Report Back from San Antonio Breast Cancer Symposium: Spotlight on MBC
 
COVID-19 Clinical Development
COVID-19 Clinical DevelopmentCOVID-19 Clinical Development
COVID-19 Clinical Development
 
Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018
 
Patient safety goal 4 : Tackling Antimicrobial Resistance
Patient safety goal 4  : Tackling Antimicrobial ResistancePatient safety goal 4  : Tackling Antimicrobial Resistance
Patient safety goal 4 : Tackling Antimicrobial Resistance
 
High Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEPHigh Sensitivity HIV Testing and Translational Science around PrEP
High Sensitivity HIV Testing and Translational Science around PrEP
 
Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013Presentación Hospital Dr. Negrín Paris 2013
Presentación Hospital Dr. Negrín Paris 2013
 
Zyvac TCV - The Indian Typhoid Conjugate Vaccine
Zyvac TCV - The Indian Typhoid Conjugate VaccineZyvac TCV - The Indian Typhoid Conjugate Vaccine
Zyvac TCV - The Indian Typhoid Conjugate Vaccine
 
Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)
 
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
¿Tiene utilidad el probiótico en la prevención de infecciones en el ámbito ho...
 
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASESDIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
 

Más de Shungo Yamamoto

軽症Covid-19の治療薬のまとめ20211229
軽症Covid-19の治療薬のまとめ20211229軽症Covid-19の治療薬のまとめ20211229
軽症Covid-19の治療薬のまとめ20211229Shungo Yamamoto
 
Covid19の薬物治療20210620
Covid19の薬物治療20210620Covid19の薬物治療20210620
Covid19の薬物治療20210620Shungo Yamamoto
 
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正新型コロナウイルスファイザーのワクチンについて2021年2月19日修正
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正Shungo Yamamoto
 
Covid19infectivity20200908
Covid19infectivity20200908Covid19infectivity20200908
Covid19infectivity20200908Shungo Yamamoto
 
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗いShungo Yamamoto
 
麻疹(はしか)と風疹のみかた 2019
麻疹(はしか)と風疹のみかた 2019麻疹(はしか)と風疹のみかた 2019
麻疹(はしか)と風疹のみかた 2019Shungo Yamamoto
 
インフルエンザ治療薬のまとめ2018
インフルエンザ治療薬のまとめ2018インフルエンザ治療薬のまとめ2018
インフルエンザ治療薬のまとめ2018Shungo Yamamoto
 
ヘルペス脳炎の治療
ヘルペス脳炎の治療ヘルペス脳炎の治療
ヘルペス脳炎の治療Shungo Yamamoto
 
インフルエンザ予測スコア
インフルエンザ予測スコアインフルエンザ予測スコア
インフルエンザ予測スコアShungo Yamamoto
 

Más de Shungo Yamamoto (11)

軽症Covid-19の治療薬のまとめ20211229
軽症Covid-19の治療薬のまとめ20211229軽症Covid-19の治療薬のまとめ20211229
軽症Covid-19の治療薬のまとめ20211229
 
Covid19の薬物治療20210620
Covid19の薬物治療20210620Covid19の薬物治療20210620
Covid19の薬物治療20210620
 
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正新型コロナウイルスファイザーのワクチンについて2021年2月19日修正
新型コロナウイルスファイザーのワクチンについて2021年2月19日修正
 
Covid19infectivity20200908
Covid19infectivity20200908Covid19infectivity20200908
Covid19infectivity20200908
 
Covid19imaging20200225
Covid19imaging20200225Covid19imaging20200225
Covid19imaging20200225
 
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い
3分でわかる風邪,インフルエンザ,新型コロナウイルス感染症予防のための手洗い
 
麻疹(はしか)と風疹のみかた 2019
麻疹(はしか)と風疹のみかた 2019麻疹(はしか)と風疹のみかた 2019
麻疹(はしか)と風疹のみかた 2019
 
インフルエンザ治療薬のまとめ2018
インフルエンザ治療薬のまとめ2018インフルエンザ治療薬のまとめ2018
インフルエンザ治療薬のまとめ2018
 
ヘルペス脳炎の治療
ヘルペス脳炎の治療ヘルペス脳炎の治療
ヘルペス脳炎の治療
 
インフルエンザ予測スコア
インフルエンザ予測スコアインフルエンザ予測スコア
インフルエンザ予測スコア
 
Dca
DcaDca
Dca
 

Último

Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 

Último (20)

Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 

グラム陰性菌菌血症治療期間

  • 1. 2018/12/13 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11. https://doi.org/10.1093/cid/ciy1054
  • 2. 7 vs 14 RCT • RCT • 2 1 • P: 7 48 7 • CVC Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 3. • / CVC CVC • • • HIV 1 48 • 48 <60mmHg • 24 • / • 48 2 38℃ 1 38.5℃ 35.5℃ • • Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 4. • I 7 • C: 14 • • in vitro • • Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 5. 90 • • a. 90 b. c. • 14 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 6. 30 • Clostridium difficile • 90 • 90 • 30 0 12 • • 90 • 90 • 1.5 2.5 RIFLE Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 7. • 30 • 10 FDA Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 8. 7 4807 2169 604 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram- negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 9. • 90 45.8% 48.3% -2.6% (95% CI -10.5% to 5.3%) • Time to return to baseline activity • Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 10. • 90 • • • Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 11. Appropriate empirical therapy administered within 48 hours 260 (85.0) 242 (81.2) Bacteria type c E. Coli Klebsiella spp. Other Enterobacteriaceae Acinetobacter spp. Pseudomonas spp. Other 186 (60.8) 47 (15.3) 40 (13.1) 2 (0.7) 28 (9.2) 3 (1) 194 (65.1) 33 (11.1) 43 (14.4) 4 (1.3) 20 (6.7) 4 (1.3) MDR Gram-negative bacteremia d 58 (18.9) 51 (17.1) Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 12. Source of bacteremia Urinary tract 212 (69.3) 199 (66.8) Primary bacteremia Abdominal Respiratory Central venous catheter Skin and soft tissue 23 (7.5) 37 (12.1) 14 (4.6) 15 (4.9) 5 (1.6) 28 (9.4) 34 (11.4) 10 (3.4) 23 (7.7) 4 (1.3) Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 13. Outcome Short arm (7 days) N=306 patients Long arm (14 days) N=298 patients Risk difference (95% confidence interval) P-value Primary outcome 140 (45.8) 144 (48.3) -2.6 (-10.5 to 5.3) 0.527 90 day all-cause mortality 36 (11.8) 32 (10.7) 1.0 (-4.0 to 6.1) 0.702 Readmissions 119 (38.9) 127 (42.6) -3.7 (-11.5 to 4.1) 0.363 Extended hospitalization beyond 14 days 15 (4.9) 19 (6.4) -1.5 (-5.1 to 2.2) 0.483 Distant complications 2 (0.7) 1 (0.3) - 1.0 Relapse of bacteremia 8 (2.6) 8 (2.7) -0.07 (-2.6 to 2.5) 0.957 Suppurative complications 16 (5.2) 10 (3.4) 1.8 (-1.4 to 5.1) 0.257 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 14. New clinically or microbiologically documented infection 70 (22.9) 68 (22.8) 0.06 (-6.6 to 6.8) 0.987 Functional capacity needs assistance/dependent in ADL or bedridden at 30 150 (51.4) (292 patients) 163 (57.2) (285 patients) -5.8 (-13.9 to 2.3) 0.031 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 15. days Resistance development 33 (10.8) 29 (9.7) 1 (-3.7 to 5.9) 0.690 Time to return to baseline activity in weeks (90 days) 2 (0-8.3) (218 patients) 3 (1-12) (222 patients) 0.010 Total hospital days (90 days from randomization) - survivors 3 (1-9) (270 patients alive at day 90) 3.5 (1-10) (266 patients alive at day 90) 0.923 Total hospital days (90 days from randomization) – all 4 (1-10) 4 (1-12) 0.603 Duration of appropriate antibiotic therapy for bacteremia 7 (7.0-8.0) 14.0 (14.0-14.0) <0.001 Total antibiotic days from culture collection to day 90 post randomization 10.0 (9.0-18.0) (270 patients alive at day 90) 16.0 (15.0-22.0) (266 patients alive at day 90) <0.001 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 16. Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.
  • 17. Supplementary Table 1: Type of antibiotics according to study group Type of antibiotics a Short arm (306 patients) Long arm (298 patients) Cephalosporins 157 (51.3) 167 (56.0) Beta-lactam beta-lactamase inhibitors 72 (23.5) 63 (21.1) Quinolones b 15 (4.9) 14 (4.7) Aminoglycosides 39 (12.7) 36 (12.1) Carbapenems 23 (7.5) 16 (5.4) Trimethoprim-sulfamethoxazole 0 2 (0.7) Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11. A. Intravenous antibiotics
  • 18. Type of antibiotics a Short arm (196 patients) Long arm (242 patients)* Quinolones 151 (77.0) 172 (71.1) Beta-lactams 28 (14.3) 50 (20.7) Trimethoprim- Sulfamethoxazole 17 (8.7) 20 (8.3) B. Oral antibiotics Data are presented as numbers (percentage) a 110 patients (35.9%) In the short duration arm and 56 (18.8%) In the long duration arm completed intra-venous antibiotic course and did not receive oral antibiotics. Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. CLIN INFECT DIS. 2018 Dec 11.